Most adults with hematologic cancers, such as acute myeloid leukemia and diffuse large B-cell lymphoma, do not receive cardioprotective prophylaxis with first-line anthracycline therapy.An evaluation of more than 13,000 patients showed less than 3% with de novo AML and less than 2% with DLBCL received frontline cardioprotection with dexrazoxane or liposomal anthracycline formulations.“We had certainly hypothesized that the uptake would be low, but I don’t think we had suspected that it would be as low as it was,” Alexis C. Boulter, MD, MS, attending physician at Children’s Hospital of